Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e9e0b17a7397b2f1b810b713a0e7651 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-501 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6949 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6921 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6923 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-08 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 |
filingDate |
2018-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_496bd92bbc1fd1691e83de1a7a1488fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9900e73532c8fcf50e23d44708902d51 |
publicationDate |
2018-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2018271900-A1 |
titleOfInvention |
Reducing the proliferation of lung carcinoma cells (a549) by administration of a poly-oxygenated metal hydroxide |
abstract |
A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated metal hydroxide composition to a mammal to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated metal hydroxide composition comprises a clathrate containing free oxygen gas (O2) molecules. The carcinoma cells may comprise lung carcinoma (A549). The poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen gas molecules to a mammal when administered to the mammal. The poly-oxygenated metal hydroxide composition can be administered intravenously, directly to carcinoma cells, and orally. The composition may comprise a fluid, where the poly-oxygenated metal hydroxide composition is soluble in the fluid. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022168337-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3944735-A4 |
priorityDate |
2016-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |